These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23551110)

  • 1. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.
    Abbas N; Heyerdahl H; Bruland ØS; Brevik EM; Dahle J
    Curr Radiopharm; 2013 Jun; 6(2):78-86. PubMed ID: 23551110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
    Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
    Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Abbas N; Bruland ØS; Brevik EM; Dahle J
    Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
    PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle J; Bruland OS; Larsen RH
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
    Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
    EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
    Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
    J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
    PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
    Heyerdahl H; Røe K; Brevik EM; Dahle J
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
    Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
    Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of [
    Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
    Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
    PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
    Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
    Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
    Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
    Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.